Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-12-23Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection [Phase 3]
Phase 3 trial update assessing glecaprevir/pibrentasvir in treatment-naive/experienced, non-cirrhotic Asian adults with chronic HCV GT1-GT6 …
-
CLINICAL_TRIALS trial_result · 2019-12-18Clinical Trial Update: Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination [NA]
Clinical trial update examining how chronic Hepatitis C infection affects immune response to zoster vaccination; study terminated with resul…
-
CLINICAL_TRIALS trial_result · 2019-12-13Clinical Trial Update: eHealth Partnered Evaluation Initiative - Evaluation of the Initial Deployment of VA's Annie Texting System [NA]
A completed clinical trial evaluating the initial deployment of VA's Annie Texting System in hepatitis C patients; results posted in 2019.
-
FDA approval · 2019-12-11FDA Approved: ZEPATIER — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for ZEPATIER (elbasvir and grazoprevir) submitted by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2019-12-11Clinical Trial Update: Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients [Phase 3]
Phase 3 trial evaluating simplified 8-week monitoring for Glecaprevir/Pibrentasvir in chronic hepatitis C patients has completed with result…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-12-10Clinical Trial Update: The Dublin Zepatier Study [Phase 4]
Phase 4 clinical trial update for Zepatier (elbasvir/grazoprevir) in Hepatitis C has been terminated.
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease [Phase 2]
Phase 2 trial assessing ledipasvir/sofosbuvir in adults with chronic HCV infection on dialysis for end-stage renal disease has completed wit…
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: Surveillance and Treatment of Prisoners With Hepatitis C [Phase 4]
Phase 4 clinical trial update on surveillance and treatment of prisoners with Hepatitis C.
-
CLINICAL_TRIALS trial_result · 2019-12-05Clinical Trial Update: Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens [Phase 4]
Phase 4 trial update of Peginterferon alfa-2a, ribavirin, and epoetin beta in coinfected HCV/HIV patients not responding to prior regimens.
-
CLINICAL_TRIALS trial_result · 2019-12-05Clinical Trial Update: Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients [Phase 4]
Phase 4 trial comparing hepatic safety of Kaletra-based vs Nevirapine-based antiretroviral regimens in HIV/HCV co-infected patients; study t…
-
FDA approval · 2019-12-04FDA Approved: HARVONI — Supplemental Application (Gilead Sciences, Inc)
FDA approved a supplemental application for HARVONI (ledipasvir/sofosbuvir) submitted by Gilead Sciences, Inc., resulting in changes to the …
-
FDA approval · 2019-12-04FDA Approved: SOVALDI — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for Sovaldi (sofosbuvir) submitted by Gilead Sciences, Inc., resulting in updated labeling.
-
CLINICAL_TRIALS trial_result · 2019-12-04Clinical Trial Update: Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV [Phase 4]
Phase 4 clinical trial analyzing viral kinetics of peginterferon alfa-2a, ribavirin, and epoetin beta in patients coinfected with HCV/HIV; c…
-
CLINICAL_TRIALS research · 2019-11-26Clinical Trial Update: Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages [Phase 4]
Phase 4 clinical trial evaluating feasibility and effectiveness of a model to eliminate hepatitis C infection in 73 villages in Egypt.
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy [Phase 3]
Phase 3 trial update on daily-dose consensus interferon plus ribavirin for chronic hepatitis C, reporting results from completed study.
-
CLINICAL_TRIALS trial_result · 2019-11-21Clinical Trial Update: Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection [Phase 3]
Phase 3 trial update evaluating glecaprevir/pibrentasvir in treatment-naive and experienced Asian adults with chronic HCV Genotypes 1-6 with…
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy [Phase 4]
Phase 4 clinical trial update examining renal safety in patients with chronic HCV treated with sofosbuvir-containing antiviral therapy.
-
FDA approval · 2019-11-15FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)
FDA approved a supplemental application for Ledipasvir and Sofosbuvir (Asegua Therapeutics LLC).
-
FDA approval · 2019-11-15FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for Epclusa (velpatasvir/sofosbuvir) submitted by Gilead Sciences, Inc.
-
FDA approval · 2019-11-15FDA Approved: VOSEVI — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) from Gilead Sciences.
-
FDA approval · 2019-11-15FDA Approved: HARVONI — Supplemental Application (Gilead Sciences, Inc)
FDA approved a supplemental application for HARVONI (ledipasvir and sofosbuvir) submitted by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096) [Phase 4]
Phase 4 trial update on elbasvir plus grazoprevir in treatment-naïve and treatment-experienced French participants with HCV genotype 4; resu…
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease [Phase 2]
Phase 2 trial assessing sofosbuvir/velpatasvir in adults with chronic hepatitis C on dialysis for end-stage renal disease has completed, wit…
-
CLINICAL_TRIALS trial_result · 2019-10-23Clinical Trial Update: Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
Clinical trial update assessing quality of life in treatment-naïve Hepatitis C genotype 1 patients treated with ombitasvir/paritaprevir/rito…
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C [Phase 2, Phase 3]
A Phase 2/3 trial evaluating quadruple therapy with eltrombopag for thrombocytopenia in chronic hepatitis C was terminated; results posted i…